System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Laurence Bouillet is an expert in Immunology at Centre Hospitalier Universitaire de Grenoble (France). As of October 2026, ScienceLeadR ranks Laurence Bouillet in the top 1% of experts worldwide for Angioedema, Immunologic Deficiency Syndromes and Hypersensitivity. Laurence Bouillet has authored 537 publications, the most recent in 2026, and is an investigator in 41 clinical trials, 15 of them ongoing. SLR score: 2,108 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Laurence Bouillet Centre Hospitalier Universitaire de Grenoble France
2 108 ScienceLeadR Reputation 2108

Unlock

Register Login
Network Map

Immunology

Subspecialties: Hematology - Internal Medicine - Dermatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1994 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Grenoble

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 537

Citations

Citations: 12 244 1st author: 66 Last author: 106 Unique author: 12

Main journals

Rev Med Interne 151
J Allergy Clin Immunol 38
Revue française d'allergologie 34
J Allergy Clin Immunol Pract 20
Allergy 15

Best Journals

N Engl J Med 4
Lancet Infect Dis 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Long-term prophylaxis for hereditary angioedema: Navigating the switch between therapies.
PMID 42894560 — disease management, quality of life, safety, pharmaceutical preparations, angioedemas, hereditary, therapeutics, angioedema		World Allergy Organ J20260
Patient Experience with Treatment of HAE Attacks: Results from a Real-World Survey of Physicians and Their Patients.
PMID 42804082 — drug therapy, physicians, diagnosis, therapeutics, angioedema		Adv Ther20260
Berotralstat Tolerability and Effectiveness in Hereditary Angioedema: Berolife Study Results.
PMID 42603305 — pain, angioedemas, hereditary, therapeutics, angioedema, abdominal pain		Clin Transl Allergy20260
Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S.
PMID 42436759 — safety, angioedemas, hereditary, therapeutics, angioedema		J Allergy Clin Immunol Glob20260
Systems serology identifies FcR-related autoantibody signatures and functions for Sjögren's syndrome.
PMID 42310390 — serology, sjogren's syndrome, diagnosis, autoantigens		EMBO Mol Med20260

Clinical Studies 41

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 11

By phase:

Phase 3 17
N/A 12
Phase 2 5
Phase 4 4
Phase 1/Phase 2 2
Phase 3/Phase 4 1

By status:

Completed 18
Recruiting 12
Active not recruiting 6
Terminated 2
Unknown 2
Not yet recruiting 1

By type:

Interventional 31
Observational 10

By Monocentric/Multicentric:

monocentric 11
multicentric2to4 1
multicentric5to9 4
multicentricup10 25

Main Topics

Cohort/Consortium Investigators 12

Ongoing Clinical Trials

15 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
STOP HAE A Phase 3 Study of ADX 324 in HAE
2025-521352-38-00 — rna, small interfering, angioedemas, hereditary, prekallikrein, therapeutics, angioedema		Phase 3Recruiting2026
A Phase 3 Randomized Double blind Placebo controlled Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
2025-523552-31-00 — lupus erythematosus, systemic		Phase 3Recruiting2026
An Open Label Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
2023-509201-77-00 — safety, angioedemas, hereditary, therapeutics, angioedema		Phase 3Active not recruiting2022
Study to Evaluate the Efficacy and Safety of Deucrictibant for Prophylactic and On demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema
2025-522051-26-00 — safety, angioedemas, hereditary, tablets, capsules, therapeutics, angioedema		Phase 3Recruiting2026
CHAPTER 4 A long term trial of deucrictibant treatment in prophylaxis against HAE attacks in adults and adolescents
2024-516248-24-00 — safety, angioedemas, hereditary, tablets, adolescent, therapeutics, angioedema		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS